Katsura Y, Nishino S, Ohno M, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H
Medicinal Chemistry Research Laboratories and Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Company, Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan.
J Med Chem. 1999 Jul 29;42(15):2920-6. doi: 10.1021/jm9900671.
A series of 2-[(arylalkyl)guanidino]-4-[(5-acetamidomethyl)furan-2-yl]thiazole s and some 4-acetamidomethyl positional isomers were synthesized and evaluated for antimicrobial activity against Helicobacter pylori. Among the compounds that had potent antimicrobial activity (MIC < 0. 1 microgram/mL), compounds 31 and 36 additionally possessed H2 antagonist and gastric antisecretory activities. Though compound 51, an analogue incorporating a methyl group onto the furan nucleus of 36, and compound 54, a positional isomer of 51, also showed potent anti-H. pylori activity, the H2 antagonism profile was eliminated from these compounds. Thus, two types of potent anti-H. pylori agents could be derived from the same scaffold.
合成了一系列2-[(芳基烷基)胍基]-4-[(5-乙酰氨基甲基)呋喃-2-基]噻唑及其一些4-乙酰氨基甲基位置异构体，并评估了它们对幽门螺杆菌的抗菌活性。在具有强效抗菌活性（MIC < 0.1微克/毫升）的化合物中，化合物31和36还具有H2拮抗剂和胃泌酸抑制活性。尽管化合物51（在36的呋喃核上引入甲基的类似物）和化合物54（51的位置异构体）也显示出强效抗幽门螺杆菌活性，但这些化合物的H2拮抗作用特征已消失。因此，可从同一骨架衍生出两种强效抗幽门螺杆菌药物。
